283 related articles for article (PubMed ID: 34071162)
1. The Non-Coding RNA Landscape in IgA Nephropathy-Where Are We in 2021?
Pawluczyk IZA; Selvaskandan H; Barratt J
J Clin Med; 2021 May; 10(11):. PubMed ID: 34071162
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy?
Selvaskandan H; Pawluczyk I; Barratt J
Clin Kidney J; 2018 Feb; 11(1):29-37. PubMed ID: 29423198
[TBL] [Abstract][Full Text] [Related]
3. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.
Rizk DV; Maillard N; Julian BA; Knoppova B; Green TJ; Novak J; Wyatt RJ
Front Immunol; 2019; 10():504. PubMed ID: 30941137
[TBL] [Abstract][Full Text] [Related]
4. Update on treatment of immunoglobulin A nephropathy.
Zhang YM; Zhang H
Nephrology (Carlton); 2018 Oct; 23 Suppl 4():62-67. PubMed ID: 30298661
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of urinary exosomal microRNAs in IgA nephropathy.
Min QH; Chen XM; Zou YQ; Zhang J; Li J; Wang Y; Li SQ; Gao QF; Sun F; Liu J; Xu YM; Lin J; Huang LF; Huang B; Wang XZ
J Clin Lab Anal; 2018 Feb; 32(2):. PubMed ID: 28383146
[TBL] [Abstract][Full Text] [Related]
6. High serum IgA/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria ≤ 1 g/d: an observational cross-sectional study.
Gong WY; Liu M; Luo D; Liu FN; Yin LH; Li YQ; Zhang J; Peng H
BMC Nephrol; 2019 Apr; 20(1):150. PubMed ID: 31039758
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylethanolamine binding protein-4 (PEBP4) is increased in IgA nephropathy and is associated with IgA-positive B-cells in affected kidneys.
Taylor S; Pieri K; Nanni P; Tica J; Barratt J; Didangelos A
J Autoimmun; 2019 Dec; 105():102309. PubMed ID: 31402200
[TBL] [Abstract][Full Text] [Related]
8. Mapping novel immunogenic epitopes in IgA nephropathy.
Woo SH; Sigdel TK; Dinh VT; Vu MT; Sarwal MM; Lafayette RA
Clin J Am Soc Nephrol; 2015 Mar; 10(3):372-81. PubMed ID: 25542908
[TBL] [Abstract][Full Text] [Related]
9. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
Cassol CA; Bott C; Nadasdy GM; Alberton V; Malvar A; Nagaraja HN; Nadasdy T; Rovin BH; Satoskar AA
Nephrol Dial Transplant; 2020 Dec; 35(12):2123-2129. PubMed ID: 31369128
[TBL] [Abstract][Full Text] [Related]
10. Diffuse alveolar hemorrhage in IgA nephropathy: case series and systematic review of the literature.
Rajagopala S; Parameswaran S; Ajmera JS; Ganesh RN; Katrevula A
Int J Rheum Dis; 2017 Jan; 20(1):109-121. PubMed ID: 26845236
[TBL] [Abstract][Full Text] [Related]
11. Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation.
Moriyama T; Nitta K; Suzuki K; Honda K; Horita S; Uchida K; Yumura W; Tanabe K; Toma H; Nihei H; Yamaguchi Y
Clin Transplant; 2005; 19 Suppl 14():41-8. PubMed ID: 15955168
[TBL] [Abstract][Full Text] [Related]
12. The Genetics of IgA Nephropathy: An Overview from Western Countries.
Feehally J; Barratt J
Kidney Dis (Basel); 2015 May; 1(1):33-41. PubMed ID: 27536663
[TBL] [Abstract][Full Text] [Related]
13. IgA Nephropathy in Children: A Multicenter Study in Poland.
Mizerska-Wasiak M; Turczyn A; Such A; Cichoń-Kawa K; Małdyk J; Miklaszewska M; Pietrzyk J; Rybi-Szumińska A; Wasilewska A; Firszt-Adamczyk A; Stankiewicz R; Szczepańska M; Bieniaś B; Zajączkowska M; Pukajło-Marczyk A; Zwolińska D; Siniewicz-Luzeńczyk K; Tkaczyk M; Gadomska-Prokop K; Grenda R; Demkow U; Pańczyk-Tomaszewska M
Adv Exp Med Biol; 2016; 952():75-84. PubMed ID: 27573641
[TBL] [Abstract][Full Text] [Related]
14. The IgA nephropathy treatment dilemma.
Appel GB; Waldman M
Kidney Int; 2006 Jun; 69(11):1939-44. PubMed ID: 16641925
[TBL] [Abstract][Full Text] [Related]
15. Urinary sediment miRNAs reflect tubulointerstitial damage and therapeutic response in IgA nephropathy.
Liang S; Cai GY; Duan ZY; Liu SW; Wu J; Lv Y; Hou K; Li ZX; Zhang XG; Chen XM
BMC Nephrol; 2017 Feb; 18(1):63. PubMed ID: 28201996
[TBL] [Abstract][Full Text] [Related]
16. Emerging Modes of Treatment of IgA Nephropathy.
Maixnerova D; Tesar V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260613
[TBL] [Abstract][Full Text] [Related]
17. The landscape and diagnostic potential of T and B cell repertoire in Immunoglobulin A Nephropathy.
Huang C; Li X; Wu J; Zhang W; Sun S; Lin L; Wang X; Li H; Wu X; Zhang P; Xu G; Wang H; Liu H; Liu Y; Chen D; Zhuo L; Li W; Yang H; Wang J; Wang L; Liu X
J Autoimmun; 2019 Feb; 97():100-107. PubMed ID: 30385082
[TBL] [Abstract][Full Text] [Related]
18. A pilot and comparative study between pathological and serological levels of immunoglobulin and complement among three kinds of primary glomerulonephritis.
Dong J; Peng T; Gao J; Jia X; Yan G; Wang Y
BMC Immunol; 2018 Jun; 19(1):18. PubMed ID: 29925312
[TBL] [Abstract][Full Text] [Related]
19. A non-invasive diagnostic model of immunoglobulin A nephropathy and serological markers for evaluating disease severity.
Han QX; Wang Y; Zhu HY; Zhang D; Gao J; Liu ZS; Cai GY; Chen XM
Chin Med J (Engl); 2019 Mar; 132(6):647-652. PubMed ID: 30855344
[TBL] [Abstract][Full Text] [Related]
20. Treatment of IgA nephropathy: Recent advances and prospects.
Coppo R
Nephrol Ther; 2018 Apr; 14 Suppl 1():S13-S21. PubMed ID: 29606258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
